Entero Therapeutics rescinds 2024 ImmunogenX merger, retains $695K AP; names new CFO

GridAI Technologies Corp.

Rescission Agreement with ImmunogenX LLC signed March 24, 2025; unwinds the March 2024 merger.
Closing conditions include shareholder approval by June 30, 2025, lender consent, and resignation of director Jack Syage.
Company retains ~$695,000 of ImmunogenX accounts payable; ImmunogenX remains responsible for ~$9.28M secured debt.
Anna Skowron appointed CFO effective March 3, 2025; brings 14+ years of accounting and financial reporting experience.
CEO states rescission strengthens balance sheet and refocuses value creation strategy.

item 1.01 item 5.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-25-027770
form_type: 8-K
ticker: GRDX
cik: 0001604191
company_name: GridAI Technologies Corp.
filed_at: 2025-03-25T23:59:59+00:00
discovered_at: 2026-05-14T18:03:04.164720+00:00
generated_at: 2026-05-24T05:48:11.351415+00:00
sec_items: ["1.01", "5.02", "7.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-25-027770
json_url: https://secwatch.observer/filing/0001104659-25-027770.json
markdown_url: https://secwatch.observer/filing/0001104659-25-027770.md
text_url: https://secwatch.observer/filing/0001104659-25-027770.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1604191/000110465925027770/0001104659-25-027770-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1604191/000110465925027770/tm2510211d1_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001104659-25-027770

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.